<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04251026</url>
  </required_header>
  <id_info>
    <org_study_id>DNLI-E-0002</org_study_id>
    <secondary_id>2019-004909-27</secondary_id>
    <nct_id>NCT04251026</nct_id>
  </id_info>
  <brief_title>A Study of DNL310 in Pediatric Subjects With Hunter Syndrome</brief_title>
  <official_title>A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Subjects With Hunter Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denali Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Denali Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, multiregional, open-label study to assess the safety, pharmacokinetics
      (PK), and pharmacodynamics (PD) of DNL310, an investigational central nervous system
      (CNS)-penetrant enzyme replacement therapy (ERT), designed to treat both the peripheral and
      CNS manifestations of Mucopolysaccharidosis type II (MPS II; Hunter syndrome).

      The study has two staggered cohorts: the first will enroll subjects with neuronopathic MPS II
      aged 5 to 10 years; and the second will enroll subjects with MPS II, either neuronopathic or
      non-neuronopathic, aged 2 to 18 years.

      Subjects, whose physicians feel they are deriving benefit, will have the opportunity to be
      reconsented into a safety extension for continued evaluation, if implemented.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events (AEs) including infusion-related reactions (IRRs)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine total glycosaminoglycan (GAG) concentrations</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cerebrospinal fluid (CSF) of heparan sulfate</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Maximum observed concentration (Cmax) of DNL310 in serum</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Trough concentration (Cmin) of DNL310 in serum</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Time to maximum observed concentration (Tmax) of DNL310 in serum</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUC[0-last]) of DNL310 in serum</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Area under the concentration-time curve over a dosing interval (AUC[0-τ]) of DNL310 in serum</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Apparent terminal elimination rate constant (λz) of DNL310 in serum</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Apparent terminal elimination t½ of DNL310 in serum</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: Accumulation ratio of DNL310 in serum</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of immunogenicity of DNL310 in serum, as measured by the incidence of anti-drug antibodies (ADAs) relative to baseline</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in urine concentration of heparan sulfate (HS)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in CSF of dermatan sulfate (DS)</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in urine concentration of DS</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in serum concentrations of HS and DS</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in levels of CSF biomarkers of lysosomal function</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Liver and spleen volumes as assessed by ultrasound</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Clinical Global Impression-Severity (CGI-S) score</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Global Impression-Improvement (CGI-I) score</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Parent/Caregiver Global Impression-Severity (PGI-S) score</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Parent/Caregiver Global Impression-Improvement (PGI-I) score</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Activities of Daily Living for Hunter Syndrome (ADL-HS) score</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in stool consistency, per the Bristol Stool Scale</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Six-Minute Walk Test (6MWT) for subjects ≥6 years old who are able to follow instructions at baseline</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in the toileting abilities percentage (TAP), as measured by the Toileting Abilities Survey (TAS)</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in auditory brainstem response (ABR) parameters</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in the cognitive-domain and the language- and motor-domain score and scores on either the Bayley Scales of Infant and Toddler Development (BSID-III) or the nonverbal index of the Kaufman Assessment Battery for Children (KABC-II)</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in the composite age-equivalent score and standard scores on the VABS-II</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Infant and Toddler Quality of Life Questionnaire (ITQOL) for subjects &lt;5 years of age</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Childhood Health Questionnaire Parent Form (CHQ-PF28) for subjects ≥5 years of age</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Pediatric Quality of Life Inventory Family Impact Module (PedsQL-FIM)</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Mucopolysaccharidosis II</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation followed by continuous dosing in subjects with neuronopathic MPS II</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation followed by continuous dosing in subjects with non-neuronopathic MPS II, neuronopathic MPS II, or unknown phenotype</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNL310</intervention_name>
    <description>Intravenous weekly administration</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Confirmed diagnosis of MPS II

          -  Cohort A: Subjects aged 5 to 10 years with neuronopathic MPS II

          -  Cohort B: Subjects aged 2 to 18 years with non-neuronopathic MPS II, neuronopathic MPS
             II, or unknown phenotype

          -  For subjects receiving intravenous iduronate 2-sulfatase (IDS) ERT, tolerated a
             minimum of 4 months of therapy during the period immediately prior to screening.

        Key Exclusion Criteria:

          -  Unstable or poorly controlled medical condition(s) or significant medical or
             psychological comorbidity or comorbidities that, in the opinion of the investigator,
             would interfere with safe participation in the trial or interpretation of study
             assessments

          -  Use of any CNS-targeted MPS II ERT within 3 months before study start for subjects
             aged ≥5 years, and within 6 months before study start for subjects aged &lt;5 years.

          -  Use of IDS gene therapy or stem cell therapy at any time

          -  Clinically significant thrombocytopenia, other clinically significant coagulation
             abnormality, or significant active bleeding, or required treatment with an
             anticoagulant or more than two antiplatelet agents

          -  Contraindication for lumbar punctures

          -  Have a clinically significant history of stroke, status epilepticus, head trauma with
             loss of consciousness, or any CNS disease that is not MPS II-related within 1 year of
             screening

          -  Have had a ventriculoperitoneal (VP) shunt placed, or any other brain surgery, or have
             a clinically significant VP shunt malfunction within 30 days of screening

          -  Have any clinically significant CNS trauma or disorder that, in the opinion of the
             investigator, may interfere with assessment of study endpoints or make participation
             in the study unsafe
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather Cahan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Denali Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials at Denali Therapeutics</last_name>
    <phone>Email:</phone>
    <email>clinical-trials@dnli.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huong Phan</last_name>
      <phone>510-428-3885</phone>
      <phone_ext>5917</phone_ext>
      <email>huong.phan@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Paul Harmatz, MD</last_name>
      <email>paul.harmatz@ucsf.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MPS II</keyword>
  <keyword>Hunter Syndrome</keyword>
  <keyword>nMPS II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

